Other C5 inhibitors such as crovalimab and pozelimab have shown good efficacy in achieving disease control and are well tolerated thus providing new treatment alternatives for PNH patients once fully approved. Here, C5 is linked to paroxysmal nocturnal hemoglobinuria.